1283. Safety, Tolerability, and Pharmacokinetics of BRII-778, A Modified-Release Oral Formulation of Rilpivirine in Healthy Adult Subjects

por Margolis, David A, Ma, Ji, Watkins, Michael, Wang, Yujin, Trivedi, Chetana, Wei, Xuelian, Zhong, Lijie, Patel, Kamlesh, Yan, Li, Hong, Zhi, Girardet, Jean-Luc, Xu, Lianhong
Publicado 2022

Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

por Miner, Jeffrey, Tan, Philip K., Hyndman, David, Liu, Sha, Iverson, Cory, Nanavati, Payal, Hagerty, David T., Manhard, Kimberly, Shen, Zancong, Girardet, Jean-Luc, Yeh, Li-Tain, Terkeltaub, Robert, Quart, Barry
Publicado 2016

Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

por Miner, Jeffrey N., Tan, Philip K., Hyndman, David, Liu, Sha, Iverson, Cory, Nanavati, Payal, Hagerty, David T., Manhard, Kimberly, Shen, Zancong, Girardet, Jean-Luc, Yeh, Li-Tain, Terkeltaub, Robert, Quart, Barry
Publicado 2016